Jesduvroq: Dosage, Uses | Daprodustat | Para IV Filing

Jesduvroq

Jesduvroq is an oral HIF-PHI approved for the treatment of anemia in adults with chronic kidney disease on dialysis. It was voluntarily withdrawn in the U.S. for non-safety-related reasons but remains FDA-listed.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Daprodustat
Innovator :

GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Approval Date :

01-Feb-23
NCE-1 Date :

01-Feb-27
NCE Date :

01-Feb-28
Dosage Form :

Tablet
Strength :

1mg,2mg,4mg,6mg,8mg
Therapeutic Category :

Antianemic
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

72
2026 :

107
2027 :

134
2028 :

157
2029 :

174
2030 :

185
2031 :

192

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Jesduvroq

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?